Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Altimmune (ALT) has received a new Buy rating, initiated by UBS analyst, Eliana Merle. Eliana Merle has given her Buy rating due to a ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Lexaria Bioscience (LEXX) provides the following glucagon-like peptide-1 industry update. It is no surprise that Novo Nordisk’s ...

Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...

SINGAPORE’S authorities are reviewing advertisements that telemedicine providers have put up for certain weight-loss drugs, ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.